A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients

Lipids in Health and Disease

Naseem Aslam Channa¹  Farah Naz Talpur²  Sadia Qamar Arain¹ 

[1] Institute of Biochemistry University of Sindh, Jamshoro, Pakistan;National Centre of Excellence in Analytical Chemistry, University of Sindh, Jamshoro 76080, Pakistan

关键词: Polyunsaturated fatty acid;    Saturated fatty acid;    Low density lipoprotein;    High density lipoprotein;    Triacylglycerol;    GC-FID;    Cholesterol;    Fatty acids;    Alpha-2b interferon;    Hepatitis C virus;   

Others  :  1233341
DOI  :  10.1186/s12944-015-0119-x

 received in 2015-07-31, accepted in 2015-09-14,  发布年份 2015

【 摘 要 】

Background

To study the effect of Interferon (INF) alpha-2b therapy on the serum lipids and fatty acid (FA) level in pre and post treated hepatitis C (HCV) patients.

Methods

Fifty samples were collected from pre and post treated patients along with age and gender matched controls. After separating serum, lipid contents were analyzed by microlab and gas chromatography.

Results

The hepatitis C infection results in hypolipidemia with reduced level of triglyceride (113 mg/dl), high density lipoprotein (37.1 mg/dl), low density lipoprotein (74.3 mg/dl), cholesterol (149.9 mg/dl) that increase the infection resolution and after the IFN treatment, the lipid profile of the patients were increased. The myristic (2.8 g/100 g) and palmitic acids (26.6 g/100 g) were significantly higher while linoleic acid (20.94 g/100 g) was significantly lower in HCV patients. The higher oleic: stearic (1.4) and palmitoleic: palmitic acid (0.2) ratios were detected in HCV patients, showing enhanced stearoyl-CoA desaturase activity. The levels of serum saturated (44.9 g/100 g) and monounsaturated FA’s (26.98 g/100 g) were higher while polyunsaturated FA’s (25.9 g/100 g) were found lower in HCV patients in comparison of controls (40.1; 25.01; 33.44 g/100 g respectively). An inverse correlation was found HCV RNA viral load and PUFA (R ²  = 0.4555). Elevated levels of serum saturated free FA (45.7 g/100 g) in HCV patients indicates stimulated lipoapoptosis.

Conclusion

The present study conclude that serum PUFA level was lower in HCV patients, hence PUFA may provide synergistic antiviral effects when given as a food supplement during the INF based anti- HCV therapy.

【 授权许可】

   
2015 Arain et al.

【 图 表 】

Fig. 1.

Figure 3.

Fig. 3.

【 参考文献 】

• [1]Gaunt MW, Sall AA, Lamballerie XD, Falconar AK, Dzhivanian TI, Gould EA. Phylogenetic relationships of flaviviruses correlate with their epidemiology, disease association and biogeography. J Virol. 2001; 82:1867-1876.
• [2]Merz A, Long G, Hiet M, Brugger B, Chlanda P, Andre P, Wieland F, Krijnse– Locker J, Bartenschlager R. Biochemical and morphological properties of Hepatitis C virus particles and determination of their Lipidome. J Biol Chem. 2011; 286:3018-3032.
• [3]Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen B, Yang H. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS ONE. 2012; 7:e47687,1-10.
• [4]Perz JF, Armstrong GL, Farrington AL, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45:529-538.
• [5]Luby SP, Kamruddin K, Shah AA, Omair A, Pahsa O, Khan AJ, McCormick JB, Hoodbhouy F, Fisher- hoch S. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol Infect. 1997; 119:349-356.
• [6]Attaullah S, Khan S, Ali I. Hepatitis C virus genotypes in Pakistan: a systemic review. Virol J. 2011; 8:1-6. BioMed Central Full Text
• [7]Ye J, DeBose-Boyd RA. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb Perspect Biol. 2011; 3:a004754.
• [8]Lambert JE, Bain VG, Ryan EA, Thomson ABR, Clandinin MT. Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology. 2013; 57:1697-1704.
• [9]Raza A, Mittal S, Sood GK. Interferon-associated retinopathy during the treatment of chronic hepatitis C. J Viral Hepatol. 2013; 20:593-599.
• [10]Umar M, Bilal M. Hepatitis C, a mega menace: a Pakistani perspective. JPMS. 2012; 2:68-72.
• [11]Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatol. 2007; 46:1548-1563.
• [12]Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, Watkins SM, Sanyal AJ. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatol. 2009; 50:1827-1838.
• [13]Miyake T, Hiasa Y, Hirooka M, Tokumoto Y, Watanable T, Furukawa S, Ueda T, Yamaoto S, Kumagi T, Miyaoka H, Abe M, Matsuura B, Onji M. High serum palmitic acid is associated with low antiviral effects of interferon-based therapy for hepatitis C virus. Lipids. 2012; 47:1053-1062.
• [14]Busch MP, Shafer K. Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment. Clin Infect Dis. 2005; 40:959-61.
• [15]Mastoi AA, Devrajani BR, Shah SZA, Rohopoto Q, Memon SA, Bloch M, Qureshi GA, Sami W. Metabolic investigations in patients with hepatitis B and C. World J Gastroenterol. 2010; 16:603-607.
• [16]Arain SQ, Talpur FN, Channa NA. Clinical evaluation and serum lipid profile between individuals with acute hepatitis C. Int J Biochem Res Rev. 2015; 6(1):37-45.
• [17]Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, Lee SH, Kim HS, Kim BS. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clin Mol Hepatol. 2014; 20:38-46.
• [18]Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in hepatitis C Virus/HIV–coinfected persons: the AIDS Clinical Trials Group A5178 study. Clin Infect Dis. 2012; 55:631-8.
• [19]Boemeke L, Bassani L, Marroni CA, Bertaso C, Gottschall CBA. Lipid profile in cirrhotic patients and its relation to Clinical outcome. ABCD Arq Bras Cir Dig. 2015; 28:132-135.
• [20]Arendt BM, Mohammad SS, Aghdassi E, Pratino NR, David WLM, Ngyen A, Guindi M, Shermen M, Heathcote EJ, Allard JP. Hepatic fatty acid composition differ between chronic hepatitis C patients with and with out steatosis. J Nutri. 2009; 139:691-695.
• [21]Cory KE, Kane E, Monroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long term follow-up. Hepatol. 2009; 50:1030-1037.
• [22]Vere CC, Streba CT, Streba L, Rogoveanu I. Lipid serum profile in patients with viral liver Cirrhosis. Med Princ Prac. 2012; 21:566-568.
• [23]Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, Mchutchison JG, McCarthy JJ. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatol. 2010; 51:1904-1911.
• [24]Scicchitano P, Cameli M, Maiello M, Modesti PA, Muiesan ML et al.. J Funct Foods. 2014; 6:11-32.
• [25]Barone M, Viggiani MT, Amoruso A, Schiraldi S, Zito A, Devito F, Cortese F, Gesualdo M, Brunetti N, Leo AD, Scicchitano P, Ciccone MM. Endothelial dysfunction correlates with liver fibrosis in chronic HCV infection. Gastroenterol Res Prac. 2015; 2015:682174.
• [26]Cicconea MM, Principib M, Ierardic E, Leob AD, Riccia G, Carbonaraa S, Gesualdoa M, Devitoa F, Zitoa A, Cortesea F, Scicchitanoa P. Inflammatory bowel disease, liver diseases and endothelial function: is there a linkage? J Cardiovasc Med. 2015; 16:11-21.
• [27]Irmisch G, Hoeppner J, Thome J, Richter J, Fernow A, Reisinger EC, Lafrenz M, Loebermann M. Serum fatty acids, antioxidants, and treatment response in hepatitis C infection: greater polyunsaturated fatty acid and antioxidant levels in hepatitis C responders. J Clin Lipidol. 2011; 5:288-293.
• [28]Leu GZ, Lin TY, Hsu JT. Anti-HCV activities of selective polyunsaturated fatty acids. Biochem Biophys Res Commun. 2004; 318:275-280.
• [29]Miyake T, Akbar SM, Yoshida O, Chen S, Hiasa Y, Matsuura B, Abe M, Onji M. Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with nonalcoholic fatty liver disease. J Gastroenterol. 2010; 45:859-867.
• [30]Huang H, Chen Y, Ye J. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci U S A. 2007; 104:18666-18670.
• [31]Kapadia SB, Chisari VF. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. PNAS. 2005; 15:2561-2566.
• [32]Sharookh B, Kapadia CFV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. PNAS. 2005; 102:2561-2566.
• [33]Koziel MJ. Immunology of viral hepatitis. Am J Med. 1996; 100:98-109.
• [34]Bureau C, Bernad J, Chaouche N, Orfila C, Beraud M, Gonindard C. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem. 2001; 276:23077-83.
• [35]Murakami Y, Nagai A, Kawakami T, Hino K, Kitase A, Hara Y, Okuda M, Okita K, Okita M. Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis Cpatients during combination therapy of interferon α-2b and ribavirin. Nutrition. 2006; 22:114-122.
• [36]Malhi H, Bronk SF, Werneburg NW, Gores GJ. Hepatocyte lipoapoptosis free fatty acids induce JNK-dependent. J Biol Chem. 2006; 281:12093-12101.